StemCell Therapy

In this day and age, corporations are really able to do virtually anything and everything they could want. If they wish to open a new office or launch a new division, they are often able to do so. Why then, are so many companies turning to philanthropic measures? Let's take a look.

Public Pressure

Nowadays, brand loyalty can often mean nothing to customers. While you once would have picked one company and stayed with them for your entire life, this is not the case any longer. If a brand does something that is not approved of by many of their customers, there is a chance that they will leave and go to a competitor.

As a result, many corporations have turned to philanthropic pursuits. This is a great way for them to respond to the concerns of their customers while also acknowledging some of the major events and issues currently facing us worldwide. For example, many corporations are making a commitment to going carbon-neutral within their business dealings. While this will require an awful lot of work on their part, and might also involve some serious redirection within the business, it is a fantastic move that will satisfy old clients and potentially attract new ones too.

Caring for Causes

Of course, it is not just the public who have control over these philanthropic pursuits. Company directors and CEOs are also directing their corporations towards issues and areas that they personally care about.

Two great examples here are Tej Kohli and Bill Gates. Tej Kohli is the founder of the philanthropic Tej Kohli Foundation which is engaged in several missions around the world. In particular, they are committed to trying to eliminate corneal blindness, one of the most common types of blindness in the world. Bill Gates and his wife Melinda set up the Bill and Melinda Gates Foundation. They have been engaged in healthcare philanthropy to help improve the living conditions for many thousands of people all across the world.

Uplifting Others

As there continues to be a growing wealth gap between the top percentiles of our society, corporations are beginning to look into ways they can offer help to some of those lower down. This could be in the form of a scholarship to attend higher education, or it could be through the form of work experience within the company.

It could even be as simple as constructing a local community centre for everyone to use. There are many small ways that a corporation can provide better opportunities to those in poorer areas. We never know what someone can achieve when given the right tools for success.

This is a trend that is most definitely not going away. With more and more corporations turning to philanthropic efforts, we are likely to see a lot of good come out of this world in the future. Take a look at some of your favourite companies to see what they are doing, or even look at some of the paths that you could adopt as a business owner.

Read the rest here:
Why Corporations Are Turning To Philanthropy - International Business Times UK

The National Research & Training Center on Blindness & Low Vision (NRTC) is proud to announce our receipt of another competitive national grant. This grant, Independent Living Services for Older Individuals Who Are Blind Training and Technical Assistance, is sponsored by the Rehabilitation Services Administration under the U.S. Department of Education. This 5-year grant, which provides approximately $3 million in funding, begins October 1, 2020.

Sylvia Stinson-Perez is the project director for this grant known as the OIB-TAC. She is excited to take the strong foundation from the last five years of the NRTCs work on this grant and add new and innovative projects. There are three major products related to this grant:

Michele McDonnall, NRTC Director, is happy that the funding will allow the NRTC to continue to improve the provision of services to older individuals who are blind.

Read more from the original source:
The NRTC Awarded Second Major National Grant | The National Research and Training Center on Blindness and Low Vision - Mississippi State Newsroom

Two recent studies by a UB researcher could help increase safety and minimize expense for patients undergoing glaucoma surgery.

The studies were conducted over several years by Asher Weiner, clinical associate professor in the Department of Ophthalmology in the Jacobs School of Medicine and Biomedical Sciences at UB. Weiner is affiliated with UBMD Ophthalmology at the Ross Eye Institute.

Glaucoma is one of the leading causes of blindness in people over the age of 60. It is a progressive condition in which the optic nerve, which is vital for vision, is damaged, often by abnormally high pressure in the eye (intraocular pressure, or IOP). This high pressure occurs when there is a buildup of fluid (aqueous humor) inside the eye, and in order to prevent blindness from glaucoma, IOP must be reduced to a safe level.

The first study was published in the Journal of Glaucoma in May. This retrospective, interventional research was conducted in a private glaucoma and cataract practice in Albany, New York, between 2014 and 2016. Weiner was affiliated with St. Peters Hospital in Albany at that time. He moved to Buffalo in 2017.

In this study, researchers sought to compare the safety and success rate of two different types of minimally invasive glaucoma surgery, or MIGS.

Instead of creating or implanting artificial drainage systems into the eye to reduce IOP procedures with increased intra- and postoperative risk most MIGS procedures utilize and enhance the eyes natural drainage system, increasing the drainage out of the eye and thereby reducing IOP.

The eyes drainage system is naturally restricted by the trabecular meshwork, the so-called strainer in the sink, Weiner says. Most MIGS procedures either remove a significant portion of this natural barrier, or bypass it using a tiny stent.

Weiner conducted the first MIGS in Michigan 12 years ago. Since then, as the success of MIGS has been demonstrated and confirmed, manufacturers have begun to develop devices to insert through the trabecular meshwork to achieve better flow out of the natural drain. There is a significant cost difference among different types of MIGS, ranging from $300-$650 with no implanted stent, to $1,750 with a stent.

In this study, Weiner compared two different types of MIGS with and without a stent over several years to also determine if the extra cost is justified for the patient and to the health care system.

He compared the surgical outcomes in patients who had two different types of MIGS in their eyes one that included implanting a stent in one eye, and one without a stent in the other eye. The objective, he says, was to examine whether the outcomes are the same, and whether a higher expense is justified.

The research found that the original method, without implanting the stent, does a better job than the stent, he says.

The bottom line is that the expensive device was less effective than the more economical original method, he says.

The second study was published online ahead of print in July in the journal Ophthalmology Glaucoma. Like the earlier research, it was a retrospective, interventional study conducted in Weiners Albany private practice between 2014 and 2016.

When lower-risk surgeries such as MIGS are insufficient to protect the optic nerve from progressive glaucoma damage, tube shunt implantation is a more effective method to reduce intraocular pressure to a safer level. However, this more aggressive procedure could increase intra- and postoperative risks.

According to the American Academy of Ophthalmology, the principal postoperative risk following tube shunt implantation into the anterior chamber of the eye (the location in the eye where tubes have traditionally been placed) is corneal decompensation and failure, leading to loss of vision and a need for corneal transplantation in an attempt to restore vision.

Thus, Weiner explains, the drawback to implanting tubes into the anterior chamber of the eye is that the tube is placed too close to the cornea, leading to corneal endothelial cell damage and corneal failure over time.

The alternative method is to insert the tube shunt behind the iris through an area called the ciliary sulcus instead of into the anterior chamber, thereby hiding the tubes behind the iris far enough from the cornea to prevent corneal damage and long-term visual loss.

Weiner has been working to further develop this surgical method for the past 12 years, and has presented his results through multiple publications and presentations.

In this study, the authors compared the rate of decline in corneal endothelial cell density following sulcus tube shunt implantation. The research showed that the rate of cell loss following sulcus tubes was a non-statistically significant 8% over two years, compared to a statistically significant loss of 20% to 30% following tubes implanted into the anterior chamber.

There was still loss, but not as dire when the tube shunt was inserted through the sulcus, and none of our patients demonstrated clinical corneal damage, Weiner says. This was the first time this was demonstrated.

The researchers also measured cell loss in eyes with glaucoma that were not being treated with shunts. Those eyes also showed cell loss (3%) over the two-year period, Weiner says.

Our findings strengthen the argument for how tube shunts should be implanted to protect our patients long-term vision, he says. But since our surgical methods require a higher skill level and may require a slightly longer operative time, many surgeons still prefer the old method.

However, in recent years, researchers have seen greater conversion to sulcus tubes around the world, he adds.

Co-authors on both studies include Weiners sons, Adam J. Weiner and Yotam Weiner from Beaumont Hospital, Oakland University William Beaumont School of Medicine in Royal Oak, Michigan.

Read the rest here:
Comparisons of glaucoma surgeries show certain techniques are safer, more effective - UB Now: News and views for UB faculty and staff - University at...

The Food and Drug Administration continues to add hand sanitizers to a list of products that should be avoided, with the list climbing to 196.

Many of the recalled products contain methanol or 1-propanol, which are very dangerous. Only ethyl alcohol and isopropyl alcohol (also known as 2-propanol) are acceptable types of alcohol in hand sanitizer, according to the FDA.

The complete list can befound on the FDAs site.

FDA test results also showed some hand sanitizers had much lower levels of active ingredient than listed on the label. The CDC recommends alcohol-based hand sanitizers have at least 60% ethyl alcohol (sometimes listed as alcohol on the label).

Other products were found with false or misleading claims on labels, including false claims that the brand prevents the spread of COVID-19 or protects you from viruses or bacteria for a certain period of time.

Methanol, or methyl alcohol, is used to make rocket fuel and antifreeze and should never be rubbed on your skin or swallowed. Swallowing or drinking hand sanitizers contaminated with methanol can cause serious health problems, including permanent blindness, and death, according to the FDA.

1-Propanol or 1-propyl alcohol is used to make industrial solvents and can also be toxic when swallowed. Swallowing or drinking a hand sanitizer with 1-propanol can result in decreased breathing and heart rate, among other serious symptoms, and can lead to death, the FDA says.Symptoms of exposure can include confusion, decreased consciousness and slowed pulse and breathing.

The FDA also says hand sanitizer should never be used on pets. If your pet gets hand sanitizer on their skin or accidentally ingests it (such as by chewing the bottle), the FDA says to contact your veterinarian or an animal poison control service immediately.

Read this article:
More products added to FDA hand sanitizer recall list - FOX40

Angela Elam

(PRESS RELEASE) CHICAGO Fight for Sight, the first nonprofit organization in the United States to promote eye research, and Prevent Blindness, the nations oldest voluntary eye health organization, announced the recipient of the 2020 Joanne Angle Public Health Award as Angela R. Elam, MD, Clinical Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan. The $25,000 grant was awarded for Dr. Elams study, Engagement in Telemedicine-based Glaucoma Screening in the Community Clinics.

The Joanne Angle Public Health Award is presented annually to research focusing on the public health side of vision and eye health. It was named for Ms. Joanne Angle who served on the National Board of Directors for Prevent Blindness, and both its Government Affairs and Audit committees, in addition to her work with the Association for Research in Vision and Ophthalmology (ARVO). Glaucoma is a group of eye conditions that damage the optic nerve, often caused by an abnormally high pressure in the eye. Those with glaucoma usually start losing their side (peripheral) vision. According to the Prevent Blindness report, The Future of Vision: Forecasting the Prevalence and Costs of Vision Problems, there are more than 3.2 million older adults in America with glaucoma. The total number is expected to increase rapidly as the U.S. population ages. Minority populations will also increasingly be affected.

The purpose of the Engagement in Telemedicine-based Glaucoma Screening in the Community Clinics study is to identify innovative strategies to better engage populations of people most at risk of vision loss from glaucoma and who are least likely to have access to an eye care provider in glaucoma screening and treatment. Both poverty and being of minority background lead to a higher risk of having glaucoma, and not getting adequate specialty treatment for glaucoma.

Dr. Elam is leading her team in implementing a telemedicine-based glaucoma screening program in two free clinics to overcome many of the logistical and psychosocial barriers to glaucoma screening. Interviews will be conducted of clinic staff, patients, and those accessing non-medical services to identify the best ways to engage community participants in the glaucoma screening program.

Telemedicine is truly making a tremendous impact in providing essential services to those who do not have the access they need to stay healthy, said Jeff Todd, president and CEO of Prevent Blindness. We are proud to give Dr. Angela Elam and her team this years Joanne Angle Public Health Award that provides funding that helps to save sight in those at highest risk for vision loss from glaucoma.

Fight for Sight is glad to partner with Prevent Blindness and congratulates Dr. Elam and her team on this award, said Michael Brogioli, executive director of Fight for Sight. Their work to engage underserved communities is especially critical during this extraordinary time.

Past recipients of the Prevent Blindness Joanne Angle Award include Brian J. Song, MD, MPH, at the Massachusetts Eye and Ear, and the Department of Ophthalmology at Harvard Medical School, for his study Glaucoma Detection in Diabetes Teleretinal Programs, and Rajeev S. Ramchandran, MD, MBA, Associate Professor of Ophthalmology, University of Rochester School of Medicine and Dentistry, for his study, Implementation Science Based Study of Teleophthalmology for Diabetic Retinopathy Surveillance.

For more information on the Fight for Sight-Prevent Blindness Joanne Angle Public Health Award, please contact Jean Song, Fight for Sight, at [emailprotected].

Read more here:
Fight for Sight and Prevent Blindness Announce Recipient of the 2020 Joanne Angle Public Health Award - InvisionMag

Why Global Citizens Should Care

When William Tasiame saw a young boy infected with rabies, he knew the child was going to die.

"He gasped for breath, hiding his face from the light. I knew the symptoms from dogs, they are similar. It is a sad death and it was the worst thing I have seen in my life," Tasiame told Global Citizen.

Tasiame studied veterinary medicine in Cuba, before going back to his home country of Ghana, where he worked as a veterinarian for 12 years. Today, he is doing research for his doctoral thesis on rabies under Christian Drosten at the Charit in Berlin, Germany.

Although rabies had always been an interest in Tasiames professional life, it wasnt until he saw that child suffering from it with his own eyes that he decided he would dedicate his research and all his energy to fighting it.

Once a person begins to show signs of having rabies, it will almost always lead to death. Signs and symptoms include headaches, nausea, vomiting, abdominal pain, diarrhea, fever, or cough. But they also include confusion, difficulty swallowing, hallucinations, and a fear of water, according to the Centers for Disease Control and Prevention (CDC).

Rabies is almost always transmitted by infected animals, mostly dogs or wild animals, such as foxes, bats, and raccoons. The virus travels through the nerves to the spinal cord and brain. It usually takes three to eight weeks between initial contact with the virus and the onset of symptoms.

"Rabies is a very brutal disease that mainly affects children and there is nothing you can do about it. There are no active ingredients or medication to combat it. Once the brain is affected, it's too late," Tabea Binger, laboratory manager of the Kumasi Center for Collaborative Research, a research facility of the Bernhard Nocht Institute for Tropical Medicine in Ghana, told Global Citizen.

Like Tasiame, Binger also wrote her doctoral thesis under Christian Drosten. She focused on viruses that infect bats and that can be transmitted to humans one of which is the rabies virus.

Having studied the virus so intensively, Binger explained that she has been vaccinated against rabies and that every year, she was tested to ensure that the protection provided by the vaccine was still sufficient.

"Most people do not have this luxury, she said. But they actually need this vaccination urgently.

Rabies is one of the diseases on the World Health Organizations (WHO) list of NTDs. These diseases are most common in tropical regions, where access to health care or water and sanitation is often poor in global comparison.

There are solutions to some of these diseases readily available, but NTDs are not prioritized globally. And while some pharmaceutical companies have donated treatments and worked to tackle these diseases, there is minimal research and development being conducted on NTDs as there is no market for the drugs.

There is no effective drug against rabies. There is a vaccine, but it requires three doses per person, which can be difficult to deliver in areas with little access to health care.

Related Stories

More than 59,000 people die every year worldwide from this NTD, with 95% of human cases occurring in Africa and Asia, according to the WHO.

"With the polio [vaccine], it is only three drops to swallow. Here in Ghana, polio workers go from door to door to distribute the vaccine to every child under 5 years of age. I have a little daughter who has just had this done,"Binger explained. "But, unfortunately, there is no such simple vaccine against rabies for humans."

What makes it all the more tragic is that more than 40% of the rabies cases affect children under 15 and most of them are caused by a dog bite, Tasiame added.

Diagnosing rabies is also a challenge as there are no efficient or cost-effective rapid tests available. This means that doctors have to find alternative methods to confirm if a child has been bitten and infected by an animal.

"Children often say that they didn't tease the dog so that they don't get into trouble it just happened that he bit out of the blue. But that makes it difficult for us to find out whether the dog had rabies or not," Tasiame said. "The only thing us vets can do is go to the village and find the dog then I can know for certain whether it was a sick dog or not."

Theoretically, it is possible to administer a post-bite vaccine to prevent death from rabies.

"This does not work very well in Ghana. As a doctor, you have to know that the patient actually has rabies. You have to be able to obtain the vaccine because it is usually only available in the capital, Accra, but the cases occur far away, in the very north of Ghana, more than 13 hours by car," Binger said.

It is also impossible to vaccinate all children that have received a dog bite as the vaccine is far too expensive.

That is why attempts are being made to instead vaccinate the disease vectors in Ghana, this generally means dogs.

Related Stories

"The primary solution to rabies is to vaccinate as many dogs as possible,"Tasiame said.

The vaccine for dogs costs about $1.75 per vaccination, which is significantly cheaper than the one for humans, which costs around $105.

"In Ghana, the method is particularly useful because there are hardly any street dogs here every dog has an owner. We just have to get hold of the dogs and raise enough money to vaccinate enough dogs,:Tasiame said.

The government of Ghana has not done much to address this health crisis, according to Tasiame. The vet says that the last government-initiated vaccination campaign against rabies in Ghana took place in the 1970s.

Last year, Tasiame launched a vaccination campaign to educate about the disease and vaccinate dogs free of charge.

"The people who are most exposed to rabies infection are poor people. The area where I started the campaign is in the north of Ghana, a poor area. I went there for the first time last year. It feels like driving to the end of the world. The roads are bad, water and electricity supplies, and health care are a problem," Tasiame said. "Last year, we vaccinated 650 dogs, but that is not enough. Statistics show that we have 1.4 million dogs in Ghana."

About 70% of the dogs would have to be vaccinated to provide sufficient protection and this would need to be done every year.

Related Stories

"This year, we have collected enough money to vaccinate about 1,000 dogs most of it comes from friends," Tasiame said, adding that him and his team have also launched a small appeal and set up a function that allows people to donate via SMS.

Through word of mouth, Tasiame and his team encourage dog owners to bring their dogs for vaccination on World Rabies Day. The campaign takes place in a well-known place in the village so that its easy for everyone to find.

Tasiame's wish is for the world to see the issue and take action on it.

"Most people who die of rabies live in rural areas they have no education, no water, no road network,"he said. "And they still have to die of a disease that could be prevented with vaccines. That hurts me the most."

Go here to read the rest:
This Preventable Disease Kills Tens of Thousands of Children Every Year - globalcitizen.org

While vitamin A is available in everything from meat and fish to colorful fruits and vegetables, there is still a risk of deficiency. Thankfully, changes to your diet and supplement use can help ensure your vitamin A levels are sufficient and stable.

Here's how to recognize the symptoms and signs of vitamin A deficiency and what you can do to treat it.

Vitamin A is a fat-soluble vitamin stored in the liver and fat tissues. It is important for a variety of bodily functions, but especially for cell differentiation. Cell differentiation occurs in adults whenever tissue renews itself either from damage or disease. It is the process by which cells become specific to parts of the body, such as brain cells, eyes cells, and skin cells, says Ashley Reaver, MS, RD, CSSD.

Due to Vitamin A's role in cell differentiation, it's important for repairing skin and maintaining eye health. Vitamin A also acts as an antioxidant, helping to reduce inflammation and supporting immune system response, says Bansari Acharya, RDN, a registered dietitian-nutritionist in Detroit, Michigan.

Learn more about the health benefits of vitamin A and how antioxidants work.

The first symptom of a vitamin A deficiency is night blindness, a condition in which people lose the ability to see in the dark, says Reaver. That's because vitamin A helps develop the molecules that help you see color that are also required for night vision.

If vitamin A deficiency is left untreated, the temporary night vision can develop into a condition known as xerophthalmia. Xerophthalmia is an umbrella term used for signs of a vitamin A deficiency in the eyes, such as corneal xerosis when the cornea appears dry and hazy. Xerophthalmia is one of the leading causes of preventable blindness worldwide, says Reaver.

Night blindness can be reversed by consuming adequate amounts of vitamin A, says Reaver. However, once a person's vision progresses to complete blindness, changing their vitamin A intake is not adequate enough to restore their sight.

Other signs of vitamin A deficiency include:

When a person does not meet their daily recommended intake of vitamin A, they become deficient. The amount of vitamin A needed varies by gender and age.

It is rare for people living in developed countries to have a vitamin A deficiency. For instance, in the United States, less than 1% of people are vitamin A deficient.

The condition is more prevalent in food-insecure countries where people don't have access to either a variety of healthy foods, an adequate amount of food, or both.

According to Reaver, the risk of becoming vitamin A deficient is especially high for the following individuals in food-insecure countries:

Vitamin A deficiency can occur in infants who are not regularly consuming enough breastmilk or formula. It can also occur in developing countries where chronic diarrhea is common in children, says Acharya.

In more developed countries, Reaver says those who are at risk for developing a vitamin A deficiency include:

These conditions can lead to a vitamin A deficiency due to malnourishment, lower intake of the nutrient, or issues with absorbing fat.

If you believe you have a vitamin A deficiency, visit a doctor as soon as possible to receive an accurate diagnosis.

Your doctor will order a blood test to determine the amount of vitamin A in your blood. Normal vitamin A ranges from 15 to 60 mcg/dL (micrograms per deciliter), so anything below 15 mcg/dL is considered deficient.

Acting swiftly can prevent long-term consequences like blindness from developing.

Vitamin A deficiency can be treated in two ways, says Reaver:

Adding vitamin A into your diet is often the first course of action, but supplements may be necessary depending on the severity of an individual's symptoms, Acharya says. How much vitamin A you need from supplementation depends on age:

Foods high in vitamin A include:

Yuqing Liu/Insider

Vitamin A deficiency is uncommon in developed countries like the United States.

People, especially children, and pregnant women, who live in countries that lack access to adequate amounts of healthy foods and clean water are at a higher risk of becoming vitamin A deficient.

Signs of deficiency include night blindness and rashes. Vitamin A deficiency can be treated through supplementation or increasing the amount of vitamin A-rich foods you eat.

See the original post here:
Signs and symptoms of vitamin A deficiency and how to treat it - Insider - INSIDER

Watch here: https://www.youtube.com/watch?feature=youtu.be&v=VVkQU91KbEs

press release: The UW has a long history of pioneering medical advancements that have transformed the world. From performing the first bone marrow transplant in the United States to cultivating the first laboratory-derived human embryonic stem cells. Now, where will UW medical research go next?

On the next Wisconsin Medicine Livestream, meet trailblazing doctors, researchers, and medical leaders who are charting a bold course to completely alter the health care landscape. During this insightful panel discussion, well explore how gene therapy and cell replacements could hold the keys to treating inherited and acquired blindness. Youll also discover the remarkable potential in xenotransplantation where nonhuman animal source organs are transplanted into human recipients. In addition, you will learn about UW Healths journey to build a multidisciplinary program to serve the community. These, and other, fascinating developments in treatment and care are happening right now at the UW and are the future of medicine. The presentation will be moderated by Robert Golden, the dean of the University of WisconsinMadisons School of Medicine and Public Health.

Our Guests:

David Gamm, professor, Department of Ophthalmology and Visual Sciences; Emmett A. Humble Distinguished Director, McPherson Eye Research Institute; Sandra Lemke Trout Chair in Eye Research

Dr. Gamms lab is at the forefront in developing cell-based therapies to combat retinal degenerative diseases (RDDs). As the director of the McPherson Eye Research Institute and a member of the Waisman Center Stem Cell Research Program, the UW Stem Cell and Regenerative Medicine Center, and the American Society for Clinical Investigation, his efforts are directed toward basic and translational retinal stem cell research. The Gamm Lab uses induced pluripotent stem cells to create retinal tissues composed of authentic human photoreceptor cells rods and cones that can detect light and initiate visual signals in a dish. The aims of his laboratory are to investigate the cellular and molecular events that occur during human retinal development and to generate cells for use in retinal disease modeling and cell replacement therapies. In collaboration with other researchers at UWMadison and around the world, the lab is developing methods to produce and transplant photoreceptors and/or retinal pigment epithelium (RPE) in preparation for future clinical trials. At the same time, the Gamm Lab uses lab-grown photoreceptor and RPE cells to test and advance a host of other experimental treatments, including gene therapies. In so doing, the lab seeks to delay or reverse the effects of blinding disorders, such as retinitis pigmentosa and age-related macular degeneration, and to develop or codevelop effective interventions for these RDDs at all stages of disease.

Dhanansayan Shanmuganayagam, assistant professor, Department of Surgery, School of Medicine and Public Health; Department of Animal and Dairy Sciences, UWMadison; director, Biomedical, and Genomic Research Group

Dr. Shanmuganayagams research focuses on the development and utilization of pigs as homologous models to close the translational gap in human disease research, taking advantage of the overwhelming similarities between pigs and humans in terms of genetics, anatomy, physiology, and immunology. He and his colleagues created the human-sized Wisconsin Miniature Swine breed that is unique to the university. The breed exhibits greater physiological similarity to humans, particularly in vascular biology and in modeling metabolic disorders and obesity. He currently leads genetic engineering of swine at the UW. His team has created more than 15 genetic porcine models including several of pediatric genetic cancer-predisposition disorders such as neurofibromatosis type 1 (NF1). In the context of NF1, his lab is studying the role of alternative splicing of the nf1 gene on the tissue-specific function of neurofibromin and whether gene therapy to modulate the regulation of this splicing can be used as a viable treatment strategy for children with the disorder.

Dr. Shanmuganayagam is also currently leading the efforts to establish the University of Wisconsin Center for Biomedical Swine Research and Innovation (CBSRI) that will leverage the translatability of research in pig models and UWMadisons unique swine and biomedical research infrastructure, resources, and expertise to conduct innovative basic and translational research on human diseases. The central mission of CBSRI is to innovate and accelerate the discovery and development of clinically relevant therapies and technologies. The center will also serve to innovate graduate and medical training. As the only center of its kind in the United States, CBSRI will make UWMadison a hub of translational research and industry-partnered biomedical innovation.

Petros Anagnostopoulos, surgeon in chief, American Family Childrens Hospital; chief, Section of Pediatric Cardiothoracic Surgery; professor, Department of Surgery, Division of Cardiothoracic Surgery

Dr. Anagnostopoulos is certified by the American Board of Thoracic Surgery and the American Board of Surgery. He completed two fellowships, one in cardiothoracic surgery at the University of Pittsburgh School of Medicine and a second in pediatric cardiac surgery at the University of California, San Francisco School of Medicine. He completed his general surgery residency at Henry Ford Hospital in Detroit. Dr. Anagnostopoulos received his MD from the University of Athens Medical School, Greece. His clinical interests include pediatric congenital heart surgery and minimally invasive heart surgery.

Dr. Anagnostopoulos specializes in complex neonatal and infant cardiac reconstructive surgery, pediatric heart surgery, adult congenital cardiac surgery, single ventricle palliation, extracorporeal life support, extracorporeal membrane oxygenation, ventricular assist devices, minimally invasive cardiac surgery, hybrid surgical-catheterization cardiac surgery, off-pump cardiac surgery, complex mitral and tricuspid valve repair, aortic root surgery, tetralogy of Fallot, coronary artery anomalies, Ross operations, obstructive cardiomyopathy, and heart transplantation.

When: Tuesday, Sept. 29, at 7 p.m. CDT

Where: Wisconsin Medicine Livestream: wiscmedicine.org/programs/ending-alzheimers

See the original post:
ONLINE: The Future of Medicine - Isthmus

News Release

Monday, September 28, 2020

NIH-funded study points to genes that control the establishment of neural circuits during early development.

In an article published in Nature Genetics, researchers confirm that about 14% of all cases of cerebral palsy, a disabling brain disorder for which there are no cures, may be linked to a patients genes and suggest that many of those genes control how brain circuits become wired during early development. This conclusion is based on the largest genetic study of cerebral palsy ever conducted. The results led to recommended changes in the treatment of at least three patients, highlighting the importance of understanding the role genes play in the disorder. The work was largely funded by the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health.

Our results provide the strongest evidence to date that a significant portion of cerebral palsy cases can be linked to rare genetic mutations, and in doing so identified several key genetic pathways involved, said Michael Kruer, M.D., a neurogeneticist at Phoenix Childrens Hospital and the University of Arizona College of Medicine - Phoenix and a senior author of the article. We hope this will give patients living with cerebral palsy and their loved ones a better understanding of the disorder and doctors a clearer roadmap for diagnosing and treating them.

Cerebral palsy affects approximately one in 323 children in the United States. Signs of the disorder appear early in childhood resulting in a wide range of permanently disabling problems with movement and posture, including spasticity, muscle weakness, and abnormal gait. Nearly 40% of patients need some assistance with walking. In addition, many patients may also suffer epileptic seizures, blindness, hearing and speech problems, scoliosis, and intellectual disabilities.

Since its first official description in 1862, scientists have hotly debated whether cerebral palsy is caused by problems at birth. For instance, it is known that babies born prematurely or who experience a lack of blood flow or oxygen during birth have a greater chance of suffering from the disorder. Later though, researchers concluded that a majority (85-90%) of all cases are congenital, or born with the disease, and some studies had suggested that cerebral palsy could be inherited. Despite this, the causes of many childrens cases had remained elusive.

Then in 2004, scientists discovered the first genetic mutation known to cause cerebral palsy. Since then several more mutations have been identified and depending on how an experiment was performed, scientists have estimated that anywhere from 2 to 30% of all cases may be linked to a misspelling in a patients DNA. In this study, the researchers provided support for a previous estimate and highlighted which genes may play a critical role in the disorder.

Cerebral palsy is one of neurologys oldest unresolved mysteries. The results from this study show how advances in genomic research provide scientists with the hard evidence they need to unravel the causes behind this and other debilitating neurological disorders, said Jim Koenig, Ph.D., program director at NINDS.

The study was led by Sheng Chih (Peter) Jin, Ph.D., assistant professor of genetics at Washington University School of Medicine, St. Louis, and Sara A. Lewis, Ph.D., a post-doc in the lab Dr. Kruer leads.

The researchers searched for what are known as de novo, or spontaneous, mutations in the genes of 250 families from the United States, China, and Australia through a collaboration made possible by the International Cerebral Palsy Genomics Consortium. These rare mutations are thought to happen when cells accidentally make mistakes copying their DNA as they multiply and divide. An advanced technique, called whole exome sequencing, was used to read out and compare the exact codes of each gene inscribed in the chromosomes of the patients with that of their parents. Any new differences represented de novo mutations that either happened while a parents sperm or egg cell multiplied or after conception.

Initially the researchers found that the cerebral palsy patients had higher levels of potentially harmful de novo mutations than their parents. Many of these mutations appeared to be concentrated in genes that are highly sensitive to the slightest changes in the DNA letter code. In fact, they estimated that about 11.9% of the cases could be explained by damaging de novo mutations. This was especially true for the idiopathic cases which had no known cause and represented the majority (62.8%) of cases in the study.

Approximately another 2% of the cases appeared to be linked to recessive, or weaker, versions of genes. This raised the estimate of cases that could be linked to genetic problems from 11.9% to 14%, as has been previously reported.

Moreover, the results led to recommendations for more tailored treatments of three patients.

The hope of human genome research is that it will help doctors find the best, most personalized, matches between treatments and diseases. These results suggest that this may be possible for some patients with cerebral palsy, said Chris Wellington, program director in the Division of Genome Sciences at the NIHs National Institute of Human Genome Research, which also provided support for the study.

When the researchers looked more closely at the results, they found that eight genes had two or more damaging de novo mutations. Four of these genes, labeled RHOB, FBXO31, DHX32, and ALK, were newly implicated in CP while the other four had been identified in previous studies.

The researchers were especially surprised by the RHOB and FBXO31 results. Two cases in the study had the same spontaneous mutation in RHOB. Likewise, two other cases had the same de novo mutation in FBXO31.

The odds of this randomly happening are incredibly low. This suggests that these genes are highly linked to cerebral palsy, said Dr. Jin.

The researchers also looked at the genes behind other brain development disorders and found that about 28% of the cerebral palsy genes identified in this study have been linked to intellectual disability, 11% to epilepsy and 6.3% to autism spectrum disorders. In contrast, the researchers found no significant overlap between cerebral palsy genes and those involved with the neurodegenerative disorder Alzheimers disease which attacks the brain later in life.

Our results support the idea that cerebral palsy is not one narrow disease but a spectrum of overlapping neurodevelopmental problems, said Dr. Lewis.

Further analysis of the results suggested that many of the genes they found in this study, including six of the eight genes that had two or more de novo mutations, control the wiring of neural circuits during early development. Specifically, these genes are known to be involved in either the construction of protein scaffolds that line the perimeters of neural circuits or in the growth and extension of neurons as they wire up.

Experiments on fruit flies, formally known as Drosophila melanogaster, supported this idea. To do this, the researchers mutated fly versions of the wiring genes they identified in the cerebral palsy patients. They found that mutations in 71% of these genes caused flies to have problems with movement, including walking, turning, and balancing. The results suggested that these genes play a critical role in movement. They estimated that there was only a 3% chance these problems would happen if they had blindly mutated any gene in the fly genome.

Treatments for cerebral palsy patients have not changed for decades, said Dr. Kruer. In the future, we plan to explore how these results can be used to change that.

These studies were supported by the NIH (NS106298, NS091299, HG006504, HD050846, HL143036), the Cerebral Palsy Alliance Research Foundation, the Doris Duke Charitable Foundation (CSDA 2014112), the Scott Family Foundation, Cure CP, the National Health and Medical Research Council (Australia; grant 1099163), The Tenix Foundation, the National Natural Science Foundation of China (U1604165), Henan Key Research Program of China (171100310200), VINNOVA (Sweden's Innovation Agency; 2015-04780), the James Hudson Brown-Alexander Brown Coxe Postdoctoral Fellowship at the Yale University School of Medicine, and the American Heart Association (18POST34060008).

https://www.ninds.nih.govis the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

Jin, S.C., Lewis, S.A.; et al., Mutations disrupting neuritogenesis genes confer risk for cerebral palsy. Nature Genetics, September 29, 2020 DOI: 10.1038/s41588-020-0695-1

###

Read the rest here:
About 14% of cerebral palsy cases may be tied to brain wiring genes - National Institutes of Health

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The GlobalTissue Banking Market, by Product (Media and Consumables, and Equipment), by Tissue (Bone, Brain & Spinal Cord, Cornea, Heart Valves, Skin, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)was valued atUS$ 1.04 billionin 2017 and is estimated to exhibit a CAGR of 10.8%during the forecast period (2018-2026),as highlighted in a new report published by Coherent Market Insights.

Transplantation is a complex area of medicine, where organs or tissues are transplanted from one person to another. Human cells and tissue transplantation are mainly performed for saving lives and/or to restore essential functions. For instance, a corneal graft can restore sight in corneal blindness, and transplantation of a human heart valve can save lives even of pediatric patients.

Moreover, government plays an important role in tissue banking establishments and management, which is expected to drive the market growth over the forecast period. For instance, in 2013, three institutes at the National Institute of Health, including the National Institute of Mental Health (NIMH), the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Child Health and Human Development (NICHD) launched a joint initiative NeuroBioBank in the U.S. It links together six large organ and tissue repositories through a common web portal.

Browse Research Report At: https://www.coherentmarketinsights.com/market-insight/tissue-banking-market-2600

Key players in tissue banking market are proactively working towards the research and development of new opportunities. For instance, in October 2018, MTF Biologics announced the formation of a new tissue recovery relationship with Regenerative Biologics, Inc. The organizations will seek to provide expanded birth-tissue donation opportunities for expectant mothers and their families and enhance patients access to high-quality placental tissues for wound care applications.

Similarly, in 2017, Natera, a leader in genetic testing launched Evercord, a new offering that enables expectant parents to collect, store, and potentially retrieve their newborns cord, blood, and tissue for therapeutic use in transplantation and regenerative medicine applications.

Browse 38 Market Data Tables and 27 Figures spread through 152 Pages and in-depth TOC on Tissue Banking Market, by Product (Media and Consumables, and Equipment), by Tissue (Bone, Brain & Spinal Cord, Cornea, Heart Valves, Skin, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Global Forecast to 2026

To know the latest trends and insights related to tissue banking market press release, click the link below: https://www.coherentmarketinsights.com/press-release/tissue-banking-market-to-surpass-us-25-billion-by-2026-1378

Key Takeaways of the Tissue Banking Market:

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website http://www.coherentmarketinsights.com

Contact:

Coherent Market Insights1001 4th Ave, #3200 Seattle, WA 98154, U.S.Email:sales@coherentmarketinsights.comUnited States of America: +1-206-701-6702United Kingdom: +44-020-8133-4027Japan: +050-5539-1737India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.

Originally posted here:
Tissue Banking Market To Find Better Growth with US$ 2.5 Billion By 2026 | CAGR: 10.8%: Coherent Mar - PharmiWeb.com

The dramatically falling costs of renewables are now a political, a media, and conversational clich. However, the claim is demonstrably false. Audited accounts show that far from getting cheaper, wind power is actually becoming more expensive. The failure of the British civil service to detect this fact and, hence, to protect the consumer and taxpayer from the consequences of the looming failure of the renewables sector raises important questions about the analytic competence of the Whitehall machine.

If we asked a random sample of broadsheet newspaper readers about the economics of offshore wind, it is practically certain that a majority of those interviewed would say they believed it was now cheap. A similar survey of investment analysts and advisors might return the same answer. Politicians and journalists would be certain about the matter. However, if pressed for evidence none of these groups could do much more than point to secondary sources. Some might remember that the Greenpeace sponsored an extensive advertising campaign in 2017, with full page adverts in the press. Others might point out that official bodies present offshore wind as the cheapest source of electricity. Those in financial circles might also indicate that almost every report or lengthy article on the future role of offshore wind power is accompanied by a chart which claims to show the rapid decline of costs over the last one or two decades, perhaps with forward projections to 2030 or 2040.

Incredible though it may seem, none of this is true. Neither offshore nor onshore wind has become cheaper; indeed, both have become more expensive over the last two decades.

How do we know this? Because one of us, Gordon Hughes, has compiled data from audited accounts on the capital and operating costs of 350 onshore and offshore wind farms in the United Kingdom, a set which covers the majority of the larger wind farms (> 10 MW capacity) built and commissioned between 2002 and 2019. It is the largest study of its kind to date and will be published shortly by the charity Renewable Energy Foundation, which John Constable directs.

In summary, analysis of the data reveals unequivocal findings:

There is an important corollary to these findings. The current set of offshore projects being constructed and planned in North Western Europe are closely akin to speculative property development. They are high risk projects that will only be able to repay lenders and offer a return to equity investors if the average wholesale market prices of power rise to at least three to four times their current level throughout North West Europe. Such a price surge would require either a large and permanent increase in the market price of gas, which experience suggests is very unlikely, or carbon taxation at 8 to 10 times current levels, rising to at least 200 per tonne of carbon dioxide at 2018 prices in 2030. Such a tax would place a heavy burden on the rest of the economy.

This has consequences for financial regulation. To discharge their responsibilities financial regulators ought to impose a heavy risk weighting on loans to offshore wind farm operators, while also advising that green equity investments are too risky for pension funds and small investors. Instead, the chiefs of the European Central Bank (ECB), the Bank of England and other regulators have urged more investment in green assets without acknowledging the risks involved.

This leads to the prospect of what is not so much a car crash as a motorway pile up in the fog of ignorance. The looming crisis will require that those who finance wind power and its related ecosystem of companies are bailed out by either taxpayers or electricity consumers. The scale of the bailout would be large: about 30 billion is at risk in the UK wind sector alone, with significantly more in Germany, the Netherlands and Denmark.

Some wind industry players may be aware that specific projects are not performing in line with general expectations there is no lack of examples reported in specialist media. However, until very recently investors have been protected by generous subsidies and operators are likely to blame project-specific factors rather than realising that the entire sector is affected. In addition, the industry in general seems believe its own propaganda, for which basic error they have only themselves to blame.

Government, we suspect, is genuinely confused. On the 24th of August while we were preparing this summary for Briefings for Britain the Department of Business, Energy and Industrial Strategy (BEIS) published its latest set of electricity generation cost estimates, Electricity Generation Costs.[1] It recommits BEIS to the view that the costs of wind power have fallen and that this technology is now amongst the cheapest available.

However, it is not difficult to show that the BEIS analysis is wholly, almost pitifully, inadequate and that it cannot be relied upon. We will discuss it in some detail below because the mistaken view that it gives of wind economics is important in itself. Even more, it provides a graphic illustration of the truly wretched quality of the analytical work that underpins policy decisions with vast implications for the United Kingdom and its people.

Before making more detailed observations, we note two general aspects of the BEIS study. First, it purports to provide estimates or forecasts of electricity generation costs for projects commissioning in 2025, 2030, 2035 and 2040. While costs at the nearest of these dates can be estimated rationally, costs a decade or more in the future are radically uncertain. To attempt even moderately precise costings, as BEIS does, suggests naivety or hubris. Who in 2000 or even in 2010 had any realistic basis for forecasting the capex and opex costs for projects that are being commissioned in 2020?

Furthermore, on examining the accompanying spreadsheet containing the Departments detailed assumptions it turns out that 94 per cent of the model parameters for the various technologies, conventional and renewable, do not change from one period to the next. This is implausible, since it must presume that there is no technological progress in those fields. Where costs do vary they are for either (a) wind and solar, or (b) a range of minor (Geothermal CHP) or novel (wave, biomass with CCS) technologies. This is unreasonable. If there are cost reductions in the renewable sector, why rule out cost reductions in the conventional sector?

Looked at in more detail this underlying bias is quite extraordinary. The rates of decline in capex and opex costs or increases in operating performance for offshore wind now a mature technology are greater and more sustained than the decline for CCGT+CCS a new and potentially critical technology.

Consequently, the BEIS projections of short-term costs are almost trivial, merely generic costs for the middle of the current decade, while the estimates of relative costs of conventional and renewable generation in the medium and longer term are at best meaningless and at worst misleading.

A second general point that should be noted is that the data used in the BEIS model is almost entirely derived from work conducted by or for the department itself. With the exception of a single reference to a National Grid ESO report, all of the sources cited for the data are BEIS publications or BEIS-commissioned reports. No attempt has been made to draw upon the growing academic and policy literature on the actual costs of building and operating various kinds of generation. There is not even a single reference to the extensive studies undertaken by the Energy Information Agency (EIA) in the US and various of the research laboratories funded by the US Department of Energy (DoE) for the example the Lawrence Berkeley National Laboratory (LBNL), the National Renewable Energy Laboratory (NREL) or the Oak Ridge National Laboratory (ORNL). Such a narrow focus is hard to justify, and indeed begins to look like a deliberate blindness in which all data is selected to fit with a pre-determined narrative.

And of course it is also true that BEIS has not made any effort to undertake the empirical investigation of audited accounts that forms the data behind the Hughes study summarised above.

Bearing these general remarks in mind, we will now compare some of the specific assumptions in the BEIS study with the results of the data compiled for this and other studies.

Conveniently BEIS has adopted the same base year (2018) for real prices as the one used for the Hughes database, so there is no need for adjustment. We will start by examining capex costs and then opex costs before looking at load factors and financial parameters. In all cases we will use the BEIS assumptions for projects commissioned in 2025, since, as noted above, the BEIS estimates for later dates are mere speculation. We will focus on onshore wind, offshore wind and large scale solar as those are the primary technologies for which BEIS has updated its assumptions and for which comparisons with actual data from company accounts are possible.

Reviewing the deficiencies of the UK governments latest estimates of generation costs we are left with a puzzle. The assumptions which underpin the BEIS estimates of the cost of generation for wind and solar power are fanciful, and do not withstand even cursory scrutiny; under close analysis they disintegrate and are a disgrace to the civil service and an embarrassment to ministers. Indeed, they are so far from the actual costs incurred by current operators and recorded in audited accounts that they are not worth further consideration, except as evidence for fundamental civil service reform. The review preceding that reform should ask how a heavily funded and staffed government department in a major economy can have strayed so far from the real world in a matter of such importance as energy supply. What on earth is going on?

The behaviour of the commercial entities involved in the renewables sector is also puzzling. If the empirical evidence is so clear, why are large companies committing substantial capital to very large projects that are almost certain to make a loss under anything like current market conditions? There are three factors that may explain this behaviour:

Once economic reality becomes undeniable, there will be a huge lobby to pass on the full costs of offshore wind to either electricity consumers or taxpayers. The obvious instrument is carbon taxation, but the increase required would be very large, and the economic harm would be politically contentious to say the least. Vast bailouts to an industry that has misrepresented its economics, whether knowingly or not, will be extremely unpopular. A government trapped between intense political opposition and the ever-widening ramifications of the financial collapse of the offshore wind sector will behave in ways that cannot be predicted confidently, but investors in renewables should be very nervous.

Gordon Hughes is Professor of Economics at the University of Edinburgh

Dr John Constable is Director of the Renewable Energy Foundation.

[1] BEIS, Electricity Generation Costs (24 August 2020). https://www.gov.uk/government/collections/energy-generation-cost-projections?utm_source=2deef6b5-8bc2-4b0b-a6a7-eecc4f289432&utm_medium=email&utm_campaign=govuk-notifications&utm_content=daily#2020

[2] https://www.gov.uk/government/publications/cost-of-capital-update-for-electricity-generation-storage-and-dsr-technologies

Related

Excerpt from:
The Costs of Offshore Wind Power: Blindness and Insight - Briefings For Britain - Briefings For Brexit

The season 1 finale of Netflix's hit TV series saw the Atlas crew complete the first half of their mission but with significant complications.

WARNING: The following contains SPOILERS for Away,season 1.

The Netflix Original TV showAwayends with a twist forRussian cosmonautMishaPopov and the situation is likely to get worse as the Atlas crew continues their mission on Mars in season 2.Awaystars Hillary Swank as Emma Green, the NASA astronaut leading humankind's first manned mission to Mars. Emma must lead her international team through multiple challenges during the 3-year trip; one such challenge is the revelation that Misha, the ship's most veteran crew member and an engineer, is rapidly loosing his ability to see.

While Netflix hasn't officially orderedAwayseason 2 yet, viewers can expect a renewal based on the show's enduring popularity.Awayis a drama series that premiered on the streaming platform on September 4, 2020. Since its debut, the show has gained a strong following online, and quickly rose to the top of Netflix's Top 10 charts.

Related:Netflix: Every Movie & TV Show Releasing In September 2020

TheAwayseason 1 finale gave the Atlas crew a much-needed win after 10 episodes of drama, tension, and general adversity. The first half of their journey was fraught with challenges even before the mission began in earnest, Emma was faced with the impossibly-difficult decision of choosing between completing her life's ambition and being present for her family during her husband's medical crisis. Realizing that staying behind would ultimately do more harm than good, she chose to proceed with the mission as planned a decision she grappled with throughout season 1. Like Emma, Misha too faced familial difficulties, but unlike his captain, his career pursuits resulted in him becoming estranged from his daughter. To add salt to the wound, season 1 gradually revealed another unfortunate ramification of his extended bouts in space: Misha has developed space blindness.

Awaymay be a fictional show, but it's based on real science. Nasahas admittedthat deep space travel may cause blindness or visual impairment in astronauts. Astudypublished in 2012 found evidence of eyeball deformities in astronauts who had been in space, and posited that that the microgravity astronauts are exposed to on long-duration missions can cause permanent changes to the optic nerve region in other words, the pressure from space flight gradually flattens the back of the eye, which in turn makes one increasingly far-sighted. This is what happens to Misha in Awayseason 1, who at one point tells fellow astronautVivian Wu that he can no longer see her face, describing it as "like an out-of-focus painting." Given that he is an engineer and previously was responsible for fixing complex machinery, his inability to seeobjectsat a close range is a significant hurdle.

Continue reading here:
Away Season 2: What Misha's Space Blindness Means For The Mars Mission - Screen Rant

This true story of resilience comes as the pandemic creates a need for greater resilience in everyone.

KNOXVILLE, Tenn Growing up in Knoxville, Chad Foster always knew that he had Retinitis Pigmentosa. And he knew the inherited genetic disorder would eventually take away his sight.

But then it actually happened when he was a student at the University of Tennessee.

"A lot of kids are asked a question when they're growing up, what do you want to be when you grow up? And none of them, and I mean none of them, said they want to grow up to be a blind guy," he said.

For a year or so he felt sorry for himself. Then he made a decision.

"I'm not responsible for my blindness, but I have to be accountable for my life and its outcomes," he said. "I have to figure out how to improve upon or how to control what's what I call inside my sphere of influence, how can I change what I can control? How can I paint a picture of my future that includes this unchangeable fact of blindness? How can I take that and then paint the vision for myself? That's something that I can get behind and get inspired to actually chase my dream."

He was 38 years old when his friend, Paul, suggested that Chad try downhill skiing.

"And I said, 'I don't know. That doesn't sound very safe, Paul.' He said, 'no, they actually have guides that can guide you down the mountain. And, you know, safely in quotes, right? That sounds interesting, I'll consider it,'" he said.

To get down the mountain, a guide follows behind him telling Chad which way to turn so he doesn't smash into trees or other skiers.

"And the texture of the voice tells you something, too. So if there's a real severe voice inflection, you know that you're on the razor's edge. So you should probably carve and really dig in to it," he said.

"I feel free. You know, for so many years I've been tethered to either a dog or a cane or something like that and out there on the mountain, you're completely free."

Conquering the slopes is not surprising.

At the University of Tennessee, Chad Foster made straight As and the Deans list and was later honored as a distinguished alumni.

He built a successful career in technology, software innovations, and motivational speaking.

He was the first blind executive to graduate from the Harvard Business School's Leadership Program.

"A lot of people can benefit from the tools and techniques that I've developed in overcoming my personal adversity, my personal adversity of going blind, and then the changes that we've seen in the business world, and the environments that I've worked in," he said. "So I've really tied that together in Blind Ambition to help people learn how to move their mindset from victim to visionary."

The book comes out in February. He's scheduled a ski trip for January. It seems like a natural way to start 2021 for a guy who knows how to pick himself up again.

"You're going to fall and if you're trying to do something great whether it's you know achieving what you want in the academic or business world or you know skiing a black diamond, you're probably going to fall in pursuit of that and you have to get comfortable with the idea that eventually I'm going to fall and it might hurt every now and then but I'll be okay," he said.

Visit link:
Knoxville native writes Blind Ambition: How To Go From Victim to Visionary - WBIR.com

On the surface, The Impending Blindness of Billie Scott is simply a coming-of-age story, a sweet and delightful portrait of the wild and wonderful people you can encounter in your early twenties, provided youre amenable. As the title implies, the titular Billie Scott is about to go blind. That would likely panic just about anyone, but Billie has the additional complication of needing to complete ten paintings for a prestigious art gallery before a two-week deadline (imposed by her impending loss of vision) is up. So she forges ahead, out of her comfortable but claustrophobic life in a student flat and out into the world, finding people to paint as she goes.

B

B

Zoe Thorogood, not so far in age from Billie, has created a book thats rich with detail without feeling fussy or overly refined. Theres a panel early on where the reader can see the bottom of Billies coffee mug, which features an intact UPC sticker, the sort of detail that grounds and humanizes a large and sometimes complicated story. The books backgrounds are filled with a cacophony of posters and people and mess, lending Billies adventure a tight and confined feeling, even after shes left the borders of her tiny room. The book is largely in grayscale, with swaths of one or two accent colors that change with the scenes and help set the tone for every interaction. The art is lovely but doesnt shy away from grime or the truly absurd, and the story is stronger for it.

Every character is drawn with a level of detail that tells you a lot about them from the moment they appear, but are still given space to surprise readers with their needs and motivations. Billies sketchbook fills quickly with drawings and observations about each one, guiding the reader to view them through her perspective as a young person who might not be aware of just how vulnerable she really is. Thorogood continues this delicate tightrope walk by giving Billie a supporting cast thats neither completely threatening nor saintly, but simply human. Her roommates are friendly despite her long-term avoidance of them, and her encounters throughout the book run the gamut from warm to awful: Shes embraced by a chaotic group of drunk women at a bachelorette party, but shes also robbed and assaulted. Overall, there are more people willing to come to her aid than want to take advantage of her, which feels honest to the world in which Billie lives.

Image: Zoe Thorogood

AdvertisementYou can skip ad after 1 second

You can go to the next slide after 1 second

Its clear that her navet and unwillingness to trust people are both hindrances to her safety and progress, and Thorogood navigates this complicated idea very well. Billie is granted space to really screw up and make mistakes, but also given second and third chancesopportunities to not only reevaluate and redefine her goals, but also reach them. Its a touching exploration of what it means to make art and how to find your people, and why both things are important. To quote Billies friend Rachel, its about why you should care.

Theres a period towards the end where the metaphors and imagery Thorogood has used thus far give way to something more explicit, and it veers towards preachiness. Billie herself even makes a joke about how cringe-inducing some of it is, which helps to defuse the awkwardnessbut its definitely not as graceful as the vast majority of the book. It feels like Thorogood doesnt trust the readers, or herself, enough to come to the books conclusions on their own, which is a shame; her storytelling up to that point is far more confident and deft than she seems to believe it was. Given this is her first published book, theres no doubt shell continue to hone her craft and use her skills for future projects that will surpass even this great book.

See the article here:
The Impending Blindness of Billie Scott tells a poignant story of youth, art, and purpose - The A.V. Club

TipRanks

In the investing game, its not only about what you buy; its about when you buy it. One of the most common pieces of advice thrown around the Street, buy low is touted as a tried-and-true tactic.Sure, the strategy seems simple. Stock prices naturally fluctuate on the basis of several factors like earnings results and the macro environment, amongst others, with investors trying to time the market and determine when stocks have hit a bottom. In practice, however, executing on this strategy is no easy task.On top of this, given the volatility that has ruled the markets over the last few weeks, how are investors supposed to gauge when a name is flirting with a bottom? Thats where the Wall Street pros come in.These expert stock pickers have identified three compelling tickers whose current share prices land close to their 52-week lows. Noting that each is set to take back off on an upward trajectory, the analysts see an attractive entry point. Using TipRanks database, we found out that the analyst consensus has rated all three a Strong Buy, with major upside potential also on tap.Progenity (PROG)Offering clear and actionable genetic results, Progenity specializes in providing testing services. The company started trading on Nasdaq in June and saw its shares tumbling 44% since then. With shares changing hands for $8.11, several members of the Street recommend pulling the trigger before it heats up.Piper Sandler analyst Steven Mah points out that even against the backdrop of COVID-19, PROG managed to deliver with its Q2 2020 performance. We are encouraged by the recovery in late Q2 2020 with 75,000 accessioned tests (~79,000 in Q1 2020), driven by noninvasive prenatal testing (NIPT) and carrier screening, the analyst noted. Expounding on this, Mah stated, Progenity did not provide guidance, but June test volumes of ~28,000 were strong (Q1 2020 monthly average was ~26,000) which we believe showcases the durability of its reproductive tests and the success that Progenity has in co-marketing and attaching carrier screening to the more essential NIPT. Of note, despite the pandemic disruptions, Progenity was able to maintain its leading pre-COVID test turnaround times.Additionally, health insurer Aetna is temporarily extending coverage of average-risk NIPT until year-end as a result of the pandemic, with the American College of Obstetricians and Gynecologists (ACOG) also expected to endorse average-risk in the future given its clinical utility, in Mahs opinion.Reflecting another positive, the fourth generation NIPT (single-molecule counting assay) test was able to measure fetal fraction, a key milestone according to Mah, and will continue to be developed into 2021. As the technology could potentially be applied to DNA, RNA, epigenetic markers and proteins for additional clinical applications such as oncology, the analyst is looking forward to the completion of the preeclampsia verification in Q4 2020 and a possible 2H21 launch. We believe preeclampsia (~2.3 billion serviceable market) is a major differentiator for Progenity, allowing them to cross-sell across the full-continuum of reproductive testing, the analyst added.If that wasnt enough, PROG signed its first GI Precision Medicine partnership agreement with a top-20 Pharma company in August. The Oral Biotherapeutic Delivery System (OBDS), an ingestible drug and device combination designed to precisely deliver biologics systemically through a needle-free liquid jet injection into the submucosal tissues of the small intestine, is set to be utilized as part of the collaboration. Mah commented, We believe Progenity can sign additional Pharma deals and look forward to the newsflow coming out on this front.To sum it all up, Mah said, We believe Progenity shares are undervalued given the robust recovery in the core testing business and multiple upcoming growth catalysts.To this end, Mah rates PROG an Overweight (i.e. Buy) along with a $17 price target. Should his thesis play out, a twelve-month gain of 105% could potentially be in the cards. (To watch Mahs track record, click here)Are other analysts in agreement? They are. Only Buy ratings, 4, in fact, have been issued in the last three months. Therefore, the message is clear: PROG is a Strong Buy. Given the $13.33 average price target, shares could climb 60% higher in the next year. (See PROG stock analysis on TipRanks)Tactile Systems Technology (TCMD)Developing at-home therapy devices, Tactile Systems Technology wants to provide new treatments for lymphedema, which occurs when the lymphatic system is impaired, disrupting normal transport of fluid within the body, and chronic venous insufficiency. Down 52% year-to-date, its $32.67 share price lands close to its $29.47 52-week low. Thus, with business trends improving, the Street is pounding the table.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the company, with COVID-19 weighing on both volumes and sales. In the second half of March, volumes were down 50% compared to the first half of the month, and TCMDs patient volumes in April and May remained challenged. That being said, trends started to improve at the end of May.Going forward, given the vast majority of TCMDs clinician customers practice in outpatient or office-based settings, we remain positive on TCMDs ability to demonstrate better insulation against COVID impacts and likely experience a greater bounce-back relative to overall med-tech volume trends, with TCMD further benefitting from its expanding using of technology to remotely engage with clinicians and support patients, Furlong explained.The analyst added, Furthermore, recent trends among some providers to prescribe Flexitouch (an advanced intermittent pneumatic compression device to self-manage lymphedema and nonhealing venous leg ulcers) earlier along the therapy process, as a means to reduce in-person contact, could provide upside near term, as well as potentially transition to a longer-term tailwind.On top of this, Furlong is also optimistic about new CEO Dan Reuvers and the reprioritization of the companys investment and market development efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments toward its Flexitouch and Entre (a pneumatic compression device used to assist in the home management of chronic swelling and venous ulcers associated with lymphedema and chronic venous insufficiency) products.Given significant under-penetration in the lymphedema/phlebolymphedema market targeted by Flexitouch alongside the large patient population with limited treatment options today targeted by the firms Head & Neck platform, we view the combination of education and clinical data as key to further developing and penetrating these markets... Going forward, we expect management to continue to compile a broad base of clinical data to support reimbursement and drive broad adoption, Furlong commented.All of this prompted Furlong to keep a Buy rating and $62 price target on the stock. This target conveys her confidence in TCMDs ability to soar 90% in the next year. (To watch Furlongs track record, click here)In general, other analysts are on the same page. With 3 Buy ratings and 1 Hold, the word on the Street is that TCMD is a Strong Buy. The $62.33 average price target brings the upside potential to 91%. (See TCMD stock analysis on TipRanks)uniQure N.V. (QURE)Last but not least we have uniQure, which delivers curative gene therapies that could potentially transform the lives of patients. Even though shares have fallen 44% year-to-date to $40, not much higher than its 52-week low of $36.20, multiple analysts still have high hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after news broke of its collaboration and licensing agreement with CSL Behring for AMT-061, QUREs gene therapy for Hemophilia B, he argues the shareholder base turnover is likely now complete as investors and QURE shift focus to next-in-line AMT-130, its AAV5 gene therapy for Huntingtons Disease (HD).Schwartz further added, With the M&A premium now out of the stock, we see the QUREs current level as an attractive buying opportunity for those investors interested in the companys up and coming CNS gene therapies, internal manufacturing, and robust intellectual property and knowhow.Looking more closely at the agreement with CSL Behring, QURE will be tasked with the completion of the pivotal Phase 3 HOPE-B trial as well as the manufacturing process validation and manufacturing supply of AMT-061.According to management, 26-week Factor IX (FIX) data from all 54 patients enrolled in the trial remains on track, and topline data from the pivotal trial is still slated to read out by YE20. It should be mentioned that in a Phase 2b dose-confirmation study, QURE reported 41% FIX activity out to one year. Additionally, Schwartz points out that with HOPE-B progressing as planned, QURE has continued its manufacturing process validation work ahead of the anticipated BLA/MAA submissions in the U.S. and EU in 2021.On top of this, as part of the deal, QURE is eligible to receive more than $2 billion including a $450 million upfront cash payment, $1.6 billion in regulatory and commercial milestones and double-digit royalties ranging up to the low-twenties percentage of net product sales.With a strengthened cash position, QURE is well funded to rapidly advance CNS assets including AMT-130 (AAV5 gene therapy for Huntingtons Disease (HD)) and AMT-150 (AAV gene therapy for Spinocerebellar Ataxia Type 3/SCA3)...We continue to believe that as QUREs CNS pipeline assets mature, the company could once again be an attractive partner to larger biopharma companies that have recently acquired many publicly traded gene therapy platforms with substantial manufacturing capabilities, Schwartz noted.Everything that QURE has going for it convinced Schwartz to reiterate an Outperform (i.e. Buy) rating. Along with the call, he attached a $67 price target, suggesting 68% upside potential from current levels. (To watch Schwartzs track record, click here)What does the rest of the Street have to say? 9 Buys and 3 Holds have been issued in the last three months, so the consensus rating is a Strong Buy. In addition, the $69.89 average price target indicates 75% upside potential. (See QURE stock analysis on TipRanks)To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

Read more here:
October Declared as Contact Lens Safety Month by Prevent Blindness to Provide Public with Information on How to Keep Eyes Healthy - Yahoo Finance

More News24 Sep 2020 | 4:20 PM

Lucknow, Sep 24 (UNI) Havells India Limited, a leading Fast-Moving Electrical Goods (FMEG) company, on Thursday announced its entry into the refrigerator segment under its consumer durable brand - Lloyd.

Kolkata, Sep 24 (UNI) To meet the diverse requirement of its Tier II and III customers, Ujjivan Small Finance Bank with a long term vision to build a better life for its people and communities announced the launch of Small Commercial Vehicle Finance.

(Rptg, correcting slug)Mumbai, Sep 24 (UNI) IndusInd Bank on Thursday slid by 7.24 pc to Rs 489.45 a major loser in 30 scrips of BSE.

Mumbai, Sep 24 (UNI) IndusInd Bank on Thursday slid by 7.24 pc to Rs 489.45 a major loser in 30 scrips of BSE.

Mumbai, Sep 24 (UNI) The BSE Sensex on Thursday slumped by 1114.82 pts to settle at 36,553.60 as selling was seen across the board amid weak Asian Market.

More here:
Why Corneal Blindness Remains a Massive Problem in India - United News of India

The agreed statement of facts offers a template for risk teams seeking to avoid a similar fate.

The complexity of Westpac's IT systems, especially when an upgrade was needed, sits at the heart of its core failures to report millions of "international fund transfer instructions" (IFTIs). These mainly related to just two of its "corresponding banks" offshore banks that Westpac receives money from and sends money to.

The relationships are critical to allow funds to move across borders. But they contain pitfalls, especially ascertaining the identity of the source of funds and customers to which money is being sent.

AUSTRAC CEO Nicole Rose at a press conference on Thursday to discuss the Westpac settlement.Alex Ellinghausen

Westpac's "Australasian Cash Management" (ACM) arrangements allowed its corresponding banks to use Westpac's direct access to the Australian clearing system to process payments. The offshore banks liked this: it reduced costs for them, by allowing them to send "structured", or aggregated, files, which was more efficient than sending payment messages, via a system known as SWIFT, for each and every payment.

When these corresponding banks send money into Australia, they must provide Westpac with an IFTI, which Westpac has to send on to AUSTRAC. In 2010, Westpac was upgrading its systems to ensure it could provide AUSTRAC with the reports in the right format. This became the source of the drama that would unfold a decade later.

The bank failed to match the tech upgrades with different ACM arrangements it had set up for different corresponding banks. Its new systems were not properly configured.

One of these was its financial crime IT system, known as Detica, built by BAE Systems. It was the primary tool for screening customers, conducting risk assessments and reporting suspicious transactions to AUSTRAC.

But to get to AUSTRAC, files received from corresponding banks went through another system, known as WIBS. They were then converted into an IFTI format, passing through Detica via another piece of software known as an integrator, and then being processed again into an IFTI that could be uploaded to AUSTRAC.

Westpac realised it had issues with the process as far back as 2010. AUSTRAC queried its IFTI reporting process in late 2011. Westpac was in regular contact with AUSTRAC in late 2010 and early 2011, as it tried to work out a reporting solution for its "structured files".

The statement of facts suggests the bank for which Westpac failed to report the vast majority of IFTIs fell outside the scope of a technical release relating to the Detica system and this was not picked up.

Then, between August 2011 and August 2012, 15 members of Westpac's IT team left to join ANZ, taking with them the bank's corporate knowledge about the complexity of the reporting system. This prevented it setting up a proper audit process that should have ensured incoming IFTIs for two banks were actually going through to AUSTRAC. The regulator described this as "an absence of appropriate end-to-end reconciliation, assurance and oversight processes for IFTI reporting".

"Westpac did not identify that over 72 per cent of all incoming IFTIs received by Westpac for the period 5 November 2013 to 3 September 2018 had not been reported," the statement says.

"As a result of the failure to file the IFTIs on time, AUSTRAC, the ATO and other law enforcement agencies have been deprived of timely information relating to over $11 billion in international payments."

Frustratingly, there were several chances for these reporting errors to have been caught by Westpac.

For example, in July 2013, AUSTRAC recommended it perform a review of its payment instructions to see if they were not being reported to the regulator. The bank prepared a "group assurance report" but it did not catch the non-reporting.

Then, in 2016, a remediation project also failed to identify the reports were not being sent in to AUSTRAC. When the non-reporting from one of the correspondent banks was identified in 2017 by a team leader, it was not escalated to senior management for action.

It was not until 2018 that the proper level of senior management was made aware of the issues. The bank swung into action but by then, the millions of legal breaches had accumulated in dramatic fashion.

The agreed statement of facts also details the holes in Westpac's due diligence that it was obliged to conduct on its corresponding banks. While it asked them questions via a questionnaire, AUSTRAC said these weren't regular enough for higher-risk banks, while the process failed to respond to new risks emerging from the sale of new products to the corresponding banks until November 2019.

There were also issues with the reporting of outgoing IFTIs, when money was being sent from Westpac abroad. One of the products that tripped up the bank was LitePay, which was set up in August 2016 to send up to $3000 to various countries overseas. Again, a systems upgrade was the root cause of the problem.

In May 2017, a technical issue affected database replication, meaning instructions for some IFTIs were not passed between Westpac systems. Then, in November 2018, another technical issue forced internal IT support teams to manually intervene to set the payment status of each transaction, but this then prevented the automated process for completing the reports which means AUSTRAC did not receive them.

Again, the statement of facts says the bank "did not have appropriate end-to-end reconciliation, assurance and oversight processes in place to identify the IFTI reporting failures relating to the LitePay outgoing IFTIs". The issue was not identified until July last year.

And then there is the failure to heed AUSTRAC's warnings, over a six-year period, about conducting proper due diligence on specific customers showing tendencies of criminal activity.

AUSTRAC published information on child exploitation risks associated with sending frequent, low-value amounts into the Philippines and some other jurisdictions in 2013. The Attorney-General's Department did the same in 2016. Westpac was briefed by AUSTRAC in December 2016 and January 2017, about adopting the new methodology to screen for suspicious payments.

But when it launched LitePay, its detection scenarios for child exploitation risk "did not adequately reflect the guidance, and did not apply to other payment channels". It was not properly implemented until October 2019.

The bank has paid a very heavy price for its failures to action AUSTRAC's requests and its governance failures to audit and proactively identify the issues. AUSTRAC said on Thursday while its contraventions were not the result of any deliberate intention to breach the legislation, "there were opportunities to prevent and detect the non-reporting and, when it was identified, failures to escalate it".

Here is the original post:
The tech failures that cost Westpac $1.3b - The Australian Financial Review

WRT the first LTTE today (9/12/20). The concept of white supremacy was not invented; it is a description of the way that some people fantasize about their rightful place in the world. However, this total lack of personal insight often results in similar thinking errors. I wonder if the writer believes that social injustice is also an invention?

The idea that social supremacy is earned by merit, must be similar to the way Pope Urban VIII believed when he cast Galileo into prison. I am confident that his belief that the Earth was the center of the universe helped reinforce his conceit that since he was the head of the church, then he must be the CORE of the center. Such dangerous thinking errors have a long and troubled history in human society. Willful blindness to facts will not help solve our social problems. Some insight might help.

Disclaimer: As submitted to the Arizona Daily Star.

Go here to see the original:
Letter: Willful Blindness to the Problem of White Supremacy - Arizona Daily Star

BOSTON MAN CHARGED WITH ASSAULT THAT LEFT THE VICTIM BLINDED IN ONE EYE - Andover Leader

September 23, 2020 4:30 pm EDT

It was on September 10th that the police officers responded to a call reporting an unarmed robbery of a 72-year-old man who said he was attacked on Freemont Street in Bostons Mattapan section, police said in a statement Sunday.

During the incident, a male suspect violently punched and kicked a 72-year-old victim, resulting in the permanent loss of vision in the victims left eye, police said.

Adding on to the blindness,The suspect, later identified by police as Willis McGhee, 50, of Boston, was also accused of ripping off the mans pants while trying to steal his wallet from his back pocket, police said.The victim was take to the hospital to be treated for his injuries.

On his arrest,McGhee voluntarily returned to a police station, where he was charged with unarmed robbery, assault and battery of a person over the age of 60, assault and battery by means of a dangerous weapon and mayhem, police said.

McGhee was expected to be arraigned Monday in Dorchester District Court, police said.

We use cookies on our website to give you the most relevant experience by remembering your preferences and visits. By clicking Accept, you consent to ALL the cookies for using your preferences. You consent will be used by 3rd party agency like google to populate advertisement as well as information as per your liking or preferences

Privacy & Cookies Policy

See original here:
BOSTON MAN CHARGED WITH ASSAULT THAT LEFT THE VICTIM BLINDED IN ONE EYE - Andover Leader

Inherited retinal diseases marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to an annual growth rate of 4.40% in the above-mentioned forecast period.

Inherited Retinal Diseasesmarket research report includes historic data, present and future market trends, environment, technological innovation, upcoming technologies and the technical progress in the allied industry. This market report contains extensive study about miscellaneous market segments and regions, emerging trends, major market drivers, challenges and opportunities in the market. The report has been generated with the comprehensive market insights and analysis that offers superior perspective of the market place. Market segmentation has also been carried out extensively in the Inherited Retinal Diseases Market business report based on a variety of parameters that include applications, verticals, deployment model, end user, and geography.

Ask For Complimentary Sample PDF| Request Athttps://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-inherited-retinal-diseases-market

The major players covered in the inherited retinal diseases market report are American Society of Gene & Cell Therapy, Spark Therapeutics, Inc., Invitae Corporation., The Choroideremia Research Foundation Inc, American Council of the Blind, Foundation Fighting Blindness, Guide Dogs for the Blind, Inc., Fighting Blindness, FIGHTING BLINDNESS CANADA, Lighthouse Guild, The RDH12 Fund For Sight, Sofia Sees Hope, Retina International, Usher Syndrome Coalition, VisionServe Alliance among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Europe is assumed to be the most lucrative inherited retinal disease market due to a relatively bigger prevalence of acquired retinal complications copulated with a higher treatment-seeking rate.

Global Inherited Retinal Diseases Market Scope and Market Size

Inherited retinal diseases market is segmented on the basis of type, treatment type and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

Based on type, inherited retinal diseases market is segmented into leber congenital amaurosis (LCA), retinitis pigmentosa, choroideremia, stargardts disease, and achromatopsia.

Inherited retinal diseases market has also been segmented based on treatment type such as gene therapy treatment, and symptomatic treatment.On the basis of distribution channel, the inherited retinal diseases market is segmented into hospital pharmacies, and retail pharmacies.

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-inherited-retinal-diseases-market

Global Inherited Retinal Diseases Market Drivers:

he growing awareness amongst the physicians and patients regarding the benefits associated with the usage of inherited retinal diseases has been directly impacting the growth of inherited retinal diseases market.

The swelling prevalence of the acquired retinal disorders is foreseen to push the growth of inherited retinal diseases treatment market. Expanding knowledge and treatment-seeking flow is anticipated to feed the germination of the inherited retinal diseases therapy business. Emphasizing knowledge of the inherited retinal disease surgery options and analysis of the condition is moreover awaited to magnify the growth of the inherited retinal disease surgery market.

The production businesses in the inherited retinal diseases market is moreover concentrating on the gene mutation-specific way for developing innovative outputs which is anticipated to accelerate the growth of inherited retinal diseases market. Numerous companies are contracting in collaborations, businesses to perform clinical experiments to promote acquired retinal disorder medication alternatives more efficiently. These certain mentioned factors are expected to drive the market growth in the forecasted period of 2020 to 2027.

TOC of Inherited retinal diseases Market Report Contains:

To know more about the study,https://www.databridgemarketresearch.com/reports/global-inherited-retinal-diseases-market

About Data Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

Visit link:
Global Inherited Retinal Diseases Market with Analysis, Trends-Industry Share, Size, Top Manufactures and Forecast Report 2020 to 2027||Invitae...